nitroparacetamol

Nitroparacetamol (NCX 701) is a nitric oxide (NO)-releasing derivative of paracetamol (acetaminophen). It was developed to combine the analgesic and antipyretic properties of paracetamol with the cytoprotective and vasodilatory effects of nitric oxide. Unlike standard paracetamol, which lacks significant anti-inflammatory activity, NCX 701 demonstrates both potent antinociceptive (pain-relieving) and anti-inflammatory effects. Its mechanism involves both inhibition of cyclooxygenase enzymes and release of NO at low but steady levels. The drug acts mainly within the central nervous system—particularly in the spinal cord—and its analgesic effect is not reversed by opioid antagonists such as naloxone, indicating a non-opioid mechanism. Developed by NicOx for potential use in pain management (acute or chronic), it showed promise in preclinical models for acute nociception and neuropathic pain but was discontinued after Phase II clinical trials[1][2][3][4][5][6].

Other names

4-acetamidophenyl 4-(nitrooxy)butanoateNO-paracetamolnitro-paracetamol